Calquence (acalabrutinib) — CareFirst (Caremark)

Initial criteria

• Authorization may be granted for treatment as a single agent or in combination with obinutuzumab.

Reauthorization criteria

• Authorization may be granted for continued treatment when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Approval duration

12 months